demonstrated compensatory upregulation of nonenzymatic antioxidant reserves, such as GSH in red blood cell lysate and plasma total free radical-trapping antioxidant potential, in term labor, which was not observed to the same extent in preterm births [380]
A Non-Natural Amino Acid for Efficient Incorporation into Proteins as a Sensitive Fluorescent Probe
It is indicated for the treatment of adult patients with R/R LBCL after two or more lines of systemic therapy, including DLBCL, HGBCL, and PMBCL ( Abecma, the first anti-BCMA CAR-T product, was approved on March 26, 2021, and is indicated for treating adult patients with R/R MM after immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies targeting CD38 ( Carvykti, a bi-epitope nanobody-based anti-BCMA CAR-T product, was approved on February 28, 2022, for adults with R/R MM after four or more prior lines of therapy, including IMiDs, PIs, and an anti-CD38 monoclonal antibody ( Aucatzyla, a CD19-directed CAR-T therapy, received approval on November 8, 2024, for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
A novel treatment for subclinical hyperthyroidism: A pilot study on the beneficial effects of l-carnitine and selenium
10.1016/S0268-960X(08)70004-3 28
M.UedaA.TakabeT